CCR2 and neoplasm: Xie et al has shown that valproic acid limits CCR2 dependent infiltration of m-MDSCs into EL-4 and B16 tumor models and, in combination with anti-PD1 enhanced anti-tumor immune responses (Xie, Ikegami, Ago, Okada, & Tachibana, 2020).